Amgen updates 2009 guidance

Amgen Inc. (NASDAQ:AMGN) said it expects 2009 EPS close to the low end of its previously expected range of $4.90-$5.05. Full-year revenue is expected to be slightly above the midpoint of previous guidance of $14.4-$14.8 billion. The Street was expecting 2009 EPS of $5.04 and revenue of $14.7 billion. Chairman, President and CEO Kevin Sharer said at the JPMorgan Healthcare Conference in San Francisco that the company's previous guidance was given before a December diabetes deal with Array BioPharma Inc. (NASDAQ:ARRY), which included a $60 million upfront payment (See BioCentury, Dec. 21, 2009). ...